Product name:
siPSMA-14 (TFA salt)
Chemical precursor for radiopharmaceutical preparations with [18F]
Molecular Weight:
1471.6 [g/mol] (m.i.),
1472.6 [g/mol] (av.)
Molecular Formula:
C61H94N13O26SiF
*Delivery time: On stock
siPSMA-14
General Information
| Product no.: | 50138 |
| Product name: | siPSMA-14 (TFA salt) |
| Sequence: | L-Glu-urea-L-Glu{D-Orn[Suc-ε-D-Lys-D-Dap(SiFA)-D-Cit-γ-L-Glu-urea-L-Glu]} |
| Molecular weight: | 1471.6 [g/mol] (m.i.), 1472.6 [g/mol] (av.) |
| Molecular formula: | C61H94N13O26SiF |
| CAS no.: | n.a. |
Product description
Chemical precursor (R&D grade) with SiFA (silicone-fluoride acceptor) for radiopharmaceutical preparations with [18F] in high radiochemical yields. Established for the imaging of prostate cancer, visualizing even small lesions.
For use by qualified personnel only.
For research use only.
Quantity
Product no. 50138: 150nmol ± 10% (TFA salt)
Packaging
Clear tubular glass vials type I (borosilicate, 2 mL) with lyophilisation stoppers and closed with aluminium caps.
Storage and Stability
Storage at -20°C (± 5°C), sealed, away from moisture and protected from light.
Certificates
Certificate of Quality
Literature
[1] Miksch, J. et al. Novel [F-18]siPSMA-14 shows favourable kinetics and high interobserver agreement in staging of prostate cancer patients; J. Nucl. Med. 2021, 61 (supplement 1), 1328.
[2] Loeffler J. et al. (2022) Blocking Studies to Evaluate Receptor-Specific Radioligand Binding in the CAM Model by PET and MR Imaging, Cancers, 2022, 14 (16), 3870
[3] Loeffler, J. et al. (2021) Comparison of Quantification of Target-Specific Accumulation of [18F]F-siPSMA-14 in the HET-CAM Model and in Mice Using PETMRI, Cancers, 2021, 13 (16), 4007
